



# Annual General Meeting

---

30 November 2021

# Disclaimer

This presentation has been prepared by ResApp Health Limited ("ResApp"). The information contained in this presentation is a professional opinion only and is given in good faith. Certain information in this document has been derived from third parties and though ResApp has no reason to believe that it is not accurate, reliable or complete, it has not been independently audited or verified by ResApp.

Any forward-looking statements included in this document involve subjective judgment and analysis and are subject to uncertainties, risks and contingencies, many of which are outside the control of, and may be unknown to, ResApp. In particular, they speak only as of the date of this document, they assume the success of ResApp's strategies, and they are subject to significant regulatory, business, competitive and economic uncertainties and risks. Actual future events may vary materially from the forward-looking statements and the assumptions on which the forward-looking statements are based. Recipients of this document (Recipients) are cautioned to not place undue reliance on such forward-looking statements. ResApp makes no representation or warranty as to the accuracy, reliability or completeness of information in this document and does not take responsibility for updating any information or correcting any error or omission which may become apparent after this document has been issued.

The information in this presentation is an overview and does not contain all information necessary to make an investment decision. It is intended to constitute a summary of certain information relating to the performance of ResApp. The information in this presentation is of a general nature and does not purport to be complete. This presentation should be read in conjunction with ResApp's other periodic and continuous disclosure announcements, which are available at <https://www.resapphealth.com.au/investor-relations/asx-announcements/>.

To the extent permitted by law, ResApp and its officers, employees, related bodies corporate and agents (Agents) disclaim all liability, direct, indirect or consequential (and whether or not arising out of the negligence, default or lack of care of ResApp and/or any of its Agents) for any loss or damage suffered by a Recipient or other persons arising out of, or in connection with, any use or reliance on this presentation or information.

This presentation is not an offer, invitation, solicitation or recommendation with respect to the subscription for, purchase or sale of any security, and neither this presentation nor anything in it shall form the basis for any contract or commitment whatsoever.

All amounts in Australian dollars unless stated otherwise.

# Board of Directors



**Roger Aston, PhD**  
**Non-Executive Chairman**

Chairman of PharmAust and Immuron, formerly Non-Exec. Director of Oncosil Medical, CEO of Mayne Pharma, Cambridge Antibody, co-founder of pSivida.



**Tony Keating, PhD**  
**CEO & Managing Director**

Formerly Director, Commercial Engagement at UniQuest, business development and engineering management roles with Exa Corporation.



**Brian Leedman**  
**Executive Director, Corporate Affairs**

Non-Executive Chairman of Neurotech and Nutritional Growth Solutions, Previously co-founded Oncosil Medical and Biolife Sciences (Imugene), Non-Executive Chairman of NeuroScientific, Chairman AusBiotech (WA) and VP, Investor Relations at pSivida.



**Chris Ntoumenopoulos**  
**Non-Executive Director**

Managing Director at Twenty 1 Corporate, formerly at RACE Oncology, Citigroup, Indian Ocean Capital and CPS Capital.



**Dr Michael Stein, PhD**  
**Non-Executive Director**

Board member of Valo Therapeutics, formerly co-founder/CEO of The Map of Medicine, founding CEO of Valo Therapeutics, Doctor Care Anywhere and OxStem.

# Leadership team



**Tony Keating, PhD**  
CEO & Managing Director

Over 10 years of experience in commercialising technology. Created the initial business strategy for ResApp and has led the company to date. Previously Director, Commercial Engagement with **UniQuest**. Prior to that held business development and engineering management roles at **Exa Corporation**.



**Brian Leedman**  
Executive Director,  
Corporate Affairs

Marketing and investor relations professional with over 15 years experience in biotech. Currently Non-Executive Chairman of **Neurotech** and **Nutritional Growth Solutions**. Previously co-founded **Oncosil Medical** and **Biolife Sciences (Imugene)**, Non-Executive Chairman of **NeuroScientific**, Chairman of **AusBiotech (WA)**, and VP, Investor Relations at **pSivida**.



**Mike Connell**  
VP, Commercial

Over 30 years of commercial experience including 13 years of health leadership experience with **GSK** (Europe & Australia), **Medibank** (private health insurance) and consulting. Prior to that, a diverse commercial background at **TRU Energy**, **Nike** and **Red Rooster**.



**Scott Savage**  
VP, Technology & Product

Over 10 years of experience in engineering and product management. Most recently Chief Product & Technology Officer at **Mable**. Prior to that held product and engineering management roles at **Google**, **YouTube** and **realestate.com.au**.



**Neroli Anderson**  
VP, Clinical,  
Quality & Regulatory

Lawyer with over 20 years of experience in risk management and compliance. Built and implemented ResApp's ISO13485 quality management system and led regulatory submissions to date. Previously risk management and compliance roles at **Flight Centre**.



**Al Rey Lunar**  
VP, Finance

CPA with over 18 years of experience in financial management, shared services and audit. Previously financial controller at **Oventus**, and financial and audit roles at **AIM**, **Moore Stephens** and **EY**.

# Leader in audio-based diagnosis of respiratory health



AI/machine learning used to analyse sound to evaluate respiratory health

The lungs are directly connected to the outside environment during a respiratory event

Sounds produced during a respiratory event contain more information than the sounds picked up by a stethoscope



Our tools are automated and avoid the need for human interpretation and the associated variability



Proven in multiple clinical trials and peer-reviewed publications



Regulatory approved in Europe and Australia with other large markets being pursued

# Respiratory health is a large addressable market

Respiratory disease diagnosis is the most common outcome from a doctor visit<sup>1</sup>



**700m+**


doctor visits p.a. for  
respiratory disease<sup>2</sup>




Respiratory diseases  
are one of the  
**most common**  
reasons for hospital  
admission<sup>3</sup>



**1b people**  
worldwide have sleep  
apnoea, 80% are  
undiagnosed



Most **modern  
pandemics** were  
caused by respiratory viruses  
(1918 Spanish flu, 1957 Asian  
flu, 2003 SARS, COVID-19)



**Upper respiratory tract:** pharyngitis, nasopharyngitis, sinusitis, laryngitis, tracheitis and sleep apnoea

**Lower respiratory tract:** asthma, pneumonia, bronchiolitis, bronchitis, COPD, GERD, pulmonary fibrosis, tuberculosis and other viral lower respiratory tract infections

<sup>1</sup> Ambulatory care visits (office and emergency department), National Ambulatory Medical Care Survey 2015

<sup>2</sup> ResApp estimate based on OECD doctor consultations per capita data (<http://stats.oecd.org>), and assuming 10% of visits (US prevalence based on NAMCS 2015 data) are for respiratory disease.

<sup>3</sup> HCUP Statistical Brief #148 (2010)



# Company timeline

2009

- A/Prof Udantha Abeyratne at The University of Queensland wins grant from the Bill & Melinda Gates Foundation

2014

- ResApp Health spun-out of the university based on A/Prof Abeyratne's research

2015

- ResApp Health listed on the ASX
- Started Breathe Easy clinical studies at Joondalup Health Campus and Perth Children's Hospital

2018

- Completed second US clinical study, SMARTCOUGH-C-2
- Core technology US patent granted
- Partnership with Lockheed Martin for US DARPA project

2017

- Started collaboration with Massachusetts General Hospital
- Completed first US clinical study, SMARTCOUGH-C

2016

- Achieved breakthrough performance in paediatric & adult clinical studies
- Won Australian Emerging Company of the Year award at the Johnson & Johnson Industry Excellence Awards

2019

- Received CE Mark & TGA approval for ResAppDx
- Achieved positive results from sleep apnoea clinical study
- Breathe Easy paediatric study published in *Respiratory Research*

2020

- Launched ResAppDx on **Coviu & Phenix Health** telehealth platforms in Australia
- Launched SleepCheck app
- Partnerships with **AstraZeneca, HealthEngine & WMA**
- Breathe Easy adult study results published in *JMIR Formative Research*

2021

- Received CE Mark & TGA clearance for wearable
- Commenced COVID-19 studies with **Phosphorus (USA) & Triomics (India)**
- Expanded partnership with **AstraZeneca**
- Supply contract with **Janssen (J&J)**
- Telehealth partnerships with **Doctors on Demand, Alodokter, Medgate & Carepath**
- Distribution agreement with **Ilara Health**
- Breathe Easy adult study results published in *British Journal of General Practice & npj Digital Medicine*

# Highlights of the past year

- ✓ FDA Pre-Submission package for cough analysis submitted, meeting scheduled for December
- ✓ CE Mark and TGA clearance for wearable device
- ✓ Started COVID-19 studies in US and India, completed recruitment in India
- ✓ SDK license to AstraZeneca for asthma program
- ✓ Ilara Health signed distribution agreement for Kenya
- ✓ Doctors on Demand signed license agreement
- ✓ Medgate signed license agreement
- ✓ Alodokter signed license agreement
- ✓ SleepCheckRx FDA 510(k) submission made
- ✓ Janssen signed license agreement



# Building partnerships to drive global adoption

## Australia



Dominated by government (Medicare) funding  
**Private payer opportunities in corporate health, insurers and triage**

## Europe



Dominated by private insurance or government funding  
**Targeting markets with high levels of private payers**

## Asia



Mixture of private payer market, government payer and hybrid systems  
**Several promising discussions underway**

## Emerging markets



Private payers, government or humanitarian agencies  
**Targeting markets with high levels of private payers**

## Pharma R&D



Pharma payers  
**Targeting clinical trials in acute respiratory disease**

COVIU

Doctors on Demand

medgate\_

ALODOKTER

ILARA HEALTH

janssen | PHARMACEUTICAL COMPANIES OF Johnson & Johnson

AstraZeneca


PHENIX HEALTH

WMA  
WORKPLACE MEDICINE AUSTRALIA


Carepath

Resapp  
HEALTH

# Our strategy



# Executing against our strategy



# A strong foundation for success



Leadership in sound analysis  
for respiratory health




Solutions address  
unmet needs




High quality clinical  
evidence



Regulatory approvals  
in Europe and  
Australia



Foundational  
partnerships driving  
adoption



Strong pipeline of  
development opportunities  
through increased indications  
in broad disease states



CEO and Managing Director

Tony Keating  
tony@resapphealth.com.au  
+61 (0) 430 180 659

Executive Director, Corporate Affairs

Brian Leedman  
brian@resapphealth.com.au  
+61 (0) 412 281 780

ResApp Health Limited

Level 12, 100 Creek Street  
Brisbane QLD 4000 Australia

[www.resapphealth.com.au](http://www.resapphealth.com.au)

Thank you!